Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

BUY
$0.73 - $1.16 $146 - $231
200 New
200 $0
Q1 2022

May 16, 2022

BUY
$6.05 - $8.65 $574 - $821
95 Added 1900.0%
100 $1,000
Q2 2021

Sep 13, 2021

BUY
$9.1 - $14.71 $45 - $73
5 New
5 $0

Others Institutions Holding KZIA

About KAZIA THERAPEUTICS LTD


  • Ticker KZIA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,111,300
  • Market Cap $87.5M
  • Description
  • Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...
More about KZIA
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.